



07-03-00 WD GAU 1644  
Box  
SEQ

PATENT  
Our Docket: P-UW 3570

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: )  
Osborne and Ramesh )  
Serial No.: 09/323,738 )  
Filed: June 1, 1999 )  
For: COMPOSITIONS AND METHODS )  
FOR TREATING DIABETES )

Group Art Unit 1644  
Examiner: F. Vander Vegt

I hereby certify that this correspondence is  
being deposited with the United States  
Postal Service as first class mail in an  
envelope addressed to: Commissioner for Patents,  
Washington, D.C. 20231, on June 28, 2000.

BOX SEQUENCE  
Commissioner for Patents  
Washington, D.C. 20231

By David A. Gay  
David A. Gay, Reg. No. 39,200

June 28, 2000  
Date of Signature

Sir:

TRANSMITTAL

Responsive to the NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR  
AMINO ACID SEQUENCE DISCLOSURES mailed June 5, 2000, the  
following are provided:

- X (1) a copy of the NOTICE;
- X (2) Communication.
- X (3) Sequence listing in computer readable form.
- \_\_\_ (4) a Preliminary Amendment;
- X (5) paper copy of sequence listing, pages 1  
through 6;
- X (6) a statement under 37 CFR §1.821(f) and (g);
- \_\_\_ (7) a Petition for Extension of Time; and
- \_\_\_ (8) a check in the amount of \$\_\_\_\_\_ to cover the fee  
for the \_\_\_-month extension of time.

RECEIVED

JUL 10 2000

TECH CENTER 1000, 2000

RECEIVED

JUL 06 2000


Inventors: Osborne and Ramesh  
Serial No.: 09/323,738  
Filed: June 1, 1999  
Page 2



Please charge any additional fees or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: June 28, 2000

  
David A. Gay,  
Registration No. 39,200  
Telephone: (858) 535-9001  
Facsimile: (858) 535-8949

CAMPBELL & FLORES LLP  
4370 La Jolla Village Drive, 7<sup>th</sup> Floor  
San Diego, California 92122  
USPTO CUSTOMER NO. 23601



PATENT

Our Docket: P-UW 3570

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
Osborne and Ramesh

Serial No: 09/323,738

Filed: June 1, 1999

For: COMPOSITIONS AND METHODS  
FOR TREATING DIABETES

Box: SEQUENCE

Asst. Commissioner for Patents  
Washington, D.C. 20231

Group Art Unit: 1644

Examiner: F. Vander Vegt

I hereby certify that this correspondence  
is being deposited with the United States  
Postal Service as first class mail in an  
envelope addressed to: Commissioner for  
Patents, Washington, D.C., 20231  
on June 28, 2000.

By:

David A. Gay, Reg. No. 39,200

June 28, 2000


Date of Signature

Sir:

COMMUNICATION

Responsive to the Notice to Comply with Requirements  
mailed June 5, 2000, submitted herewith is a computer readable  
form of the sequence listing and a paper copy. The computer  
readable form in the above-identified application is identical  
with that filed in parent application serial no. 09/185,852,  
filed on November 4, 1998.

New pages 1 through 6 are submitted herewith containing  
Sequences 1 through 11, formatted in accordance with the  
conventions set forth by PatentIn. No new matter is introduced  
by these new pages as they merely represent the sequences  
originally set forth in the application. Accordingly, entry of  
these amendments and new pages is respectfully requested.




Inventors: Osborne and Ramesh  
Serial No.: 09/323,738  
Filed: June 1, 1999  
Page 2

No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is given to charge the amount of this fee to deposit account number 03-0370.

Respectfully submitted,

June 28, 2000  
Date

  
\_\_\_\_\_  
David A. Gay  
Registration No. 89,200  
Telephone No. (858) 535-9001  
Facsimile No. (858) 535-8949

CAMPBELL & FLORES LLP  
4370 La Jolla Village Drive  
Suite 700  
San Diego, California 92122

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial ~~or substitute~~ computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial ~~or substitute~~ paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patent Software Program Support

Technical Assistance.....703-287-0200

To Purchase Patent Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**